These appointments deepen the expertise and experience within the senior leadership as Myricx scales to becomes a clinical stage company, with multiple N-myristoyltransferase inhibitor ADCs (NMTi-ADC) ...

A U of A researcher recently created a new class of drugs that targets and kills cancer cells with less damage to healthy cells.

NMT is thought to play a key role in various ... according to Myricx, its inhibitors have been shown to regress tumours in solid tumours that do not respond well to current payloads like tubulin ...